No Data
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
12 Health Care Stocks Moving In Monday's After-Market Session
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
NextCure Shares Are Trading Lower. The Company Announced Results From Its Phase 1b Study of NC410.
NextCure Presented Results of the Phase 1b Study of NC410 in Combination With Pembrolizumab at ESMO 2024
Express News | NextCure Presented Results of the Phase 1B Study of Nc410 in Combination With Pembrolizumab at Esmo 2024
No Data
No Data